VolitionRx Limited (VNRX)
NYSE: VNRX · In Vitro & In Vivo Diagnostic Substances · Henderson, NV · filing with the SEC since 1999
Who owns VolitionRx Limited
As filed with the SECHolders of 5% or more
1
Lagoda Investment Management, L.P. holds 5.9% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Sep 16, 2026 says.
Directors and officers
18
report now, of 25 people on the record since 2013. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Lagoda Investment Management, L.P.
SCHEDULE 13D/A · filed Sep 16, 2026 · Common Stock, par value $0.001 per share · 7.4% in Sep 4, 2026
Armistice Capital, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 8.72% in Nov 14, 2025
What VNRX reports owning in othersstakes of 5% or more, and other ties
6 subsidiaries in 4 countries, from the list filed with the 10-K filed Mar 31, 2026.
Insider tradesForm 4
0sales
1purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 23, 2025 to Oct 23, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Oct 23, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Reynolds Cameron John | President and CEO | 0 | $0 | 0 | 1 | $0 |